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ABSTRACT
The Biomedical Applications Team program spon­ 
sored by the National Aeronautics and Space 
Administration is an effective means for trans­ 
ferring aerospace technology to applications in 
medicine. A conceptual framework for medical 
technology transfer is presented to describe the 
transfer process in medicine and to supply a 
rationale for the Biomedical Applications Team 
methodology. Examples illustrate medical 
technology transfer at the material, design, 
and capacity levels. The roles of donor, 
recipient, and transfer agent are illustrated 
and factors essential to the success of medical 
technology transfer are summarized.
INTRODUCTION
Human cells, frozen, stored, and thawed without 
damage, may be made available for therapeutic 
use; people may benefit from the application of 
stimulating and monitoring electrodes that 
require replacement only once each week; and 
clinical information systems are demonstrating 
the potential for improved medical care without 
increased costs. While none of these medical 
advances are direct results of National Aero­ 
nautics and Space Administration (NASA) research, 
they have all benefitted from NASA technology. 
The way NASA's Biomedical Applications Teams 
stimulate such technology transfers not only 
illustrate the value of second applications of 
aerospace technology but can serve as a model 
for successful technology transfer in other 
areas.
The Space Act of 1958 required NASA to "provide 
for the widest practical and appropriate dis­ 
semination of information concerning its activity 
and the results thereof."1 The NASA Technology 
Utilization Program was initiated in 1962 to 
assist in satisfying this requirement.
In 1966, NASA established Biomedical Applications 
Teams to stimulate and facilitate the transfer 
of aerospace technology to applications in 
medicine. These teams identified medical pro­ 
blems, identified potentially applicable tech­ 
nology, and took necessary and appropriate steps 
to effect actual utilization of NASA technology 
in medicine. In the intervening years, the 
successful transfer of NASA technology to ap­ 
plications in the medical field via the 
Biomedical Applications Team program has been
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demonstrated. NASA technology has been suc­ 
cessfully applied to applications in both clinical 
medicine and in medical research. Results include 
advances in medical research, improved clinical 
diagnosis and treatment, and the introduction of 
new or improved medical products.
At present, Biomedical'Applications Teams are 
sponsored by NASA at the following institutions:
Research Triangle Institute
Post Office Box 12194
Research Triangle Park, NC 27709
Stanford University School of Medicine 
701 Welch Road 
Palo Alto, CA 94304
University of Wisconsin 
1500 Johnson Drive 
Madison, Wisconsin 54706
PROGRAM OBJECTIVES AND APPROACH
The specific objective of the Biomedical Appli­ 
cations Team program is to assist NASA in 
obtaining widespread utilization of aerospace 
technology in the medical field. Widespread 
implies that a significant sector of the medical 
community and the recipients of medical services 
should be benefitted. Implicit in this program 
objective is that utilization must be obtained 
in a relatively rapid manner.
The largest potential for rapid and widespread 
utilization of NASA technology in medicine is in 
clinical medicine. Although advances in medical 
research definitely have a beneficial impact on 
the delivery of medical services, this is, in 
general, a long term and expensive process. As 
a result, benefits from the transfer of technology 
to medical research are realized later than is the 
case in clinical medicine.
Applications of technology in clinical medicine 
usually involve the introduction of a new or 
improved, commercially available, medical product. 
Thus, the approach of the Biomedical Applications 
Team at Research Triangle Institute (RTI) in 
obtaining widespread utilization of NASA technology 
is to direct its efforts primarily to solving 
problems that involve the introduction of such 
products.
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This emphasis on achieving widespread utilization 
by commercializing NASA technology is reflected 
in the methodology of the Biomedical Applications 
Team program. The RTI team methodology is built 
around the following four activities: (1) the 
identification of medical problems and needs and 
potentially applicable NASA technologies that 
together constitute a new medical product op­ 
portunity; (2) screening of opportunities to 
identify those that represent potentially suc­ 
cessful commercial products; (3) the develop-r 
ment of commercialization strategies that take 
into account any necessary adaptation of NASA 
technology, evaluations and clinical trials, 
PDA regulations, manufacturing, marketing 
systems, and required funding; and, (4) imple­ 
mentation and monitoring of commercialization 
strategies.
The RTI Biomedical Applications Team is a multi- 
disciplinary team of engineers and scientists. 
Their educational backgrounds are physiology, 
biophysics, engineering, biochemistry, and bio- 
medical engineering; their experience includes 
basic and applied research, development., and 
marketing.
CONCEPTUAL FRAMEWORK
A conceptual framework for medical technology 
transfer is presented diagrammatically in 
Figure I. 6 The framework is basically a bipolar, 
donor-recipient model for technology transfer. 
The role of the donor, in this case NASA, is to 
reveal, disseminate, and promote technology. The 
role of the recipient, the medical community, is 
to seek out, evaluate, and utilize technology.
As explained in the Introduction, the primary 
thrust of the Biomedical Applications Team pro­ 
gram is to transfer technology by the intro­ 
duction of new and improved medical products. 
Thus, a manufacturer of those products is 
included in Figure 1 . Medical technology trans­ 
fer normally involves the identification of a 
medical problem or need within the medical 
community. In response, NASA recognizes the 
relevance of specific aerospace technology and 
makes that technology available. The manu­ 
facturer designs, develops, evaluates, and 
markets a new or improved medical product that 
incorporates the aerospace technology and that 
represents a solution to the medical problem or 
need.
The purpose of the transfer agent* is to plan, 
stimulate, and facilitate such technology trans­ 
fer. This is the role of the Biomedical 
Applications Team.
Research into the process of medical technology 
transfer at the Syracuse University Research 
Center has concluded that the donor, recipient, 
and manufacturer are frequently at cross 
purposes. The recipient is primarily and
*The terminology "linker" is frequently used 
in this context.
appropriately concerned only with solving a pro­ 
blem. The manufacturer by necessity is concerned 
with introducing a commercially viable product. 
And, the donor frequently obtains only satis­ 
faction as reward for involvement in the transfer 
process. It is the task of the transfer agent to 
bring the donor, recipient, and manufacturer 
together in such a way that each views successful 
technology transfer as the primary objective. 
Completeness of the transfer effort must be a 
major goal for all parties involved.
The specific role of the transfer agent depends 
upon the motivation, competence, and organization 
of the donor, recipient, and manufacturer. NASA 
is highly motivated to transfer aerospace 
technology to applications in non-space-related 
fields. Further, its organization is structured 
to facilitate the development of sophisticated 
and advanced technology. NASA's understanding 
of the medical industry and clinical medicine, on 
the other hand, is not extensive. The techno­ 
logical competence of the recipient is highly 
variable. Many medical researchers in large 
medical centers and teaching hospitals are 
technologically competent; the physician in 
clinical practice, in general, will not be 
technologically competent. The manufacturer of 
medical products may have a long and successful 
history of developing and marketing medical pro­ 
ducts or may be a small agressive company ex­ 
hibiting innovative behavior but lacking relevant 
experience. It is the role of the Biomedical 
Applications Team to recognize the strengths and 
weaknesses of each participant and to supply the 
motivation, competence, and institutional linkages 
to ensure success.
Technology will be interpreted as including all of 
the skills, techniques, and understanding as well 
as the materials, devices, and hardware that make 
up a specific technology.^ Technology transfer 
as used throughout this paper will refer 
specifically to "horizontal" technology transfer. 
That is, the transfer of technology from one 
situational context—the one for which the 
technology was originally developed—to another 
situational context. 9 This transfer will normally 
result in either a modification of the technology 
or a change in the situational context to which 
it is transferred.
Ruttan and Hayami have defined three levels at
which technology transfer can occur. These levels
are: 10
Level 1; Material Technology Transfer. This 
involves the transfer of hardware, unmodified, 
from one situational context to another. 
Level 2: Design Technology Transfer. In this 
case, both hardware and software may be trans­ 
ferred for the purpose of imitating the original 
technology with some modifications for a new 
application.
Level 3: Capacity Technology Transfer. This 
level involves the transfer of knowledge and 
ability so that the recipient can generate his 
own technology.
In medical technology transfer, there are only a
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few instances in which level 1, material, transfers 
occur. The transfer of physiological electrodes 
developed for use in space vehicles to use in 
clinical medicine represents a level 1 transfer. 
Most medical technology transfers are level 2 
and level 3 transfers. The redesign of an aero­ 
space component or system for application in 
medicine constitutes a level 2 transfer. The 
utilization of NASA-generated knowledge, tech­ 
niques , and procedures in the development and 
design of a new medical product constitutes a 
level 3 transfer.
BIOMEDICAL APPLICATIONS TEAM METHODOLOGY
As noted in the Introduction and indicated in 
Figure 2, the activities of the Biomedical 
Applications Team can be separated into four 
phases. Within each of these phases of the pro­ 
gram, the specific actions and responsibilities 
of the team are, to a certain extent, fixed. 
However, team methodology incorporates flexi­ 
bility that allows it to respond appropriately 
to the specific characteristics of particular 
technology transfer cases.
Identification of Opportunities
The identification of technology transfer op­ 
portunities involves; (1) the identification of 
a medical problem or need; and, (2) the identi­ 
fication of relevant aerospace technology that 
solves the medical problem or satisfies the 
medical need.
The identification of medical problems occurs 
through the direct interaction between a team 
member and a researcher or physician within a 
medical institution. At present, the RTI team 
interacts directly with medical staff at 27 
medical institutions throughout the eastern 
United States.
A study of medical technology transfer by the 
National Academy of Engineering has concluded 
that the recipient must take the lead in de­ 
fining medical problems.H This is consistent 
with the experience of the RTI team. As a result, 
the Biomedical Applications Team emphasizes 
obtaining complete and extensive descriptions of 
medical problems and needs from medical re­ 
searchers and clinicians.
Certain medical institutions and medical pro­ 
fessionals are more innovative than others.12 
Research has shown that the first hospitals to 
adopt innovations are generally large medical 
centers or teaching hospitals geographically 
close to the place where the technology was 
developed. Further, those hospitals with highly 
trained medical staff tend to be more innovative. 
The "innovative elite" in medicine generally 
act to improve the quality of health care rather 
than to achieve maximum economic efficiency. 
Finally, once a hospital has adopted an in­ 
novation, the widespread use of that innovation 
is enhanced if the innovating hospital interacts 
frequently with other medical institutions. The
Biomedical Applications Team takes into account 
these factors concerning innovative behavior of 
the medical community in its problem identifi­ 
cation activities.
There are indications that medical technology 
introduced in the past 10 to 20 years often has 
tended to increase the sophistication of medical 
diagnosis and treatment but has not contributed 
to a reduction in the cost of health care nor to 
increasing the quality of health care for the popu­ 
lation as a whole.^ This indicates that there is 
an opportunity for introducing aerospace technology 
in a manner to reduce the cost of health care or 
at least assist in containing health care costs. 
The efforts of the Biomedical Applications Team 
are directed to identifying opportunities that 
potentially reduce or contain medical costs.
Technology relevant to medical problems and needs 
is identified by a variety of techniques. Once a 
medical problem or need is specified, a com­ 
puterized information search of the aerospace 
literature is performed by one of the six In­ 
dustrial Applications Centers (lACs). The RTI 
team utilizes the services of the IAC located in 
Research Triangle Park, North Carolina—the North 
Carolina Science and Technology Research Center. 
These computerized information searches identify 
information on potentially relevant technologies.
An additional approach to identifying aerospace 
technology is the circulation of Problem State­ 
ments to NASA Field Centers. Individual medical 
problems are concisely described in Problem 
Statements. Each Problem Statement is sent to 
NASA engineers and scientists working in areas 
related to the medical problem. Responses to 
Problem Statements from these engineers and 
scientists can lead to the identification of 
technological solutions.
Finally, the Biomedical Applications Team fre­ 
quently contacts NASA scientists and engineers 
known by the team to have a strong interest in 
transferring technology to medicine. This is the 
most direct, efficient, and rapid approach to 
locating technology.
A medical problem in combination with a poten­ 
tially relevant aerospace technology constitutes 
an opportunity for technology transfer. The next 
phase of the program is the investigation of 
factors that determine which opportunities are most 
likely to be successful.
Screening
Effective screening of opportunities enables the 
RTI Biomedical Applications Team to focus on those 
opportunities with the most promise for successful 
medical solutions and commercial products. In 
order to continue work on a particular opportunity, 
the team must determine that most of the following 
requirements are satisfied:
• The solution improves medical treatment or 
diagnosis or reduces the cost of health care;
• The solution is recognized by a medical mission
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agency and the medical community as a. contri­ 
bution to improved health care;
• The solution incorporates NASA technology or 
expertise;
• The market for the new or improved product 
justifies the required capital investment and- 
production cost to the manufacturer;
• A manufacturer can be offered protection 
either by exclusive license or sudden entry of 
the product into the medical market; and,,
• The solution represents a discrete* well 'de­ 
fined transfer of technology Involving limited 
research and development effort.
These factors are evaluated by reviewing the bio- 
medical literature, market surveys* .interviews 
with industry representatives* and discussions 
with appropriate medical' staff.
Development of Strategies
The development of strategy for successful tech­ 
nology transfer must take into account product 
development and marketing* clinical trials* 
acceptance by the medical profession, and identi­ 
fication of funding sources for the various tasks 
involved ,
The previously mentioned National Academy of 
Engineering study of medical technology transfer
reached some Important conclusions concern,ing 
strategy for technology tramsfer . *•*• Successful
technology transfer requires intimate and signifi­ 
cant involvement of both the donor and recipient 
throughout the transfer process* Further, the 
involvement of industry throughout the transfer 
process is essential. Finally* the manner in 
which new technology is introduced to the medical 
field is a critical factor in its success.
The experience of the RTI Biomedical Applications
Team has confirmed these conclusions and expanded 
upon them. Industry must be involved throughout 
the transfer process and must be brought into that 
process as early as is possible., Further,, the 
involvement of industry will generally require 
some means for giving; a specific manufacturer a 
proprietary position. This may involve either an 
exclusive license or sudden entry of the new or 
improved product into the medical market,, Indus­ 
try will view new product opportunities from the 
outside as being in competition with its own 
internally generated product ideas. This means 
that opportunities for technology transfer gener­ 
ated through the Biomedical Applications Team 
program will have to compete for industry 
capital and management attention.
The acceptance of a new product by the medical 
community involves a fairly specific sequence 
of events. Following development of the 
product it must be subjected to clinical trials. 
This must be followed by publication of the 
results by a recognized medical expert. 
Generally, the product must be exhibited at 
medical meetings. This sequence of events 
normally leads to physician acceptance.
Medical marketing and distribution frequently are 
not an integral function of medical product manu­ 
facturing firms. Thus, in addition to selecting 
and obtaining the participation of a medical 
product manufacturer, the team must also identify 
and bring into the transfer process an organi­ 
zation having the capability to market and dis­ 
tribute those products.
Each specific opportunity for medical technology 
transfer will offer a new set of barriers and 
strategic options. Thus, the formation of a 
strategy is not a repeatable and specific 
activity. It is in itself a problem solving 
effort. The most important common feature of 
strategy formation is thoroughness. All con­ 
tingencies must be anticipated.
Implementation and Monitoring
•Experience in the implementation of strategy has
shown that the chance for successful technology 
transfer is increased by active involvement of 
the Biomedical Applications Team throughout the 
transfer process. By monitoring and coordinating 
the activities of the participants, minor problems 
can be prevented from becoming major obstacles.
Reports and documentation are an integral part of 
the team methodology; they are involved throughout 
the technology transfer process. Implementation 
of strategy is no exception; periodic status 
reports are issued informally to keep all parti­ 
cipants informed. Upon completion of the transfer 
process, the team prepares a technology transfer 
report documenting all important aspects of the 
transfer process.
MEDICAL TECHNOLOGY TRANSFER EXAMPLES
Three examples of the transfer of aerospace 
technology to applications in medicine are pre­ 
sented to illustrate the transfer process. The 
specific cases presented were selected: (1) to 
illustrate material, design, and capacity trans­ 
fers; (2) to elucidate the roles played by 
donor, recipient, and transfer agent; and 
(3) to emphasize other important aspects of 
technology transfer in medicine. Further, each 
case was selected such that the transfer process 
was typical of medical technology transfer at the 
material, design, and capacity levels.
Case 1: Body Surface Electrodes 
(Material Transfer)
Commercially available body surface electrodes 
have been adequate for obtaining high quality EGG 
signals for several years. These electrodes, 
however, did not allow the long-term EGG moni­ 
toring required in NASA's ground-based tests of 
human subjects.
S, A. Rositano of NASA's Ames Research Center 
developed a flexible electrode which allowed 
continuous EGG monitoring for up to eight days 
with excellent results. 5 ' 1 His first attempts
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involved suspending silver in a silicone rubber 
matrix. This system exhibited long term de­ 
gradation of the lead wire to elastomer contact. 
A subsequent attempt involved the use of a silver- 
coated nylon net fabric similar to support 
hosiery in texture and finish. This material 
was both inexpensive and exhibited stable 
resistivity. The flexible material permitted 
construction of large electrodes that did not 
restrict normal skin movement. Lead wires were 
attached by riveting or conductive epoxy. Using 
these electrodes with a gel-impregnated porous 
paper, long term monitoring of subjects was 
successful.
The Stanford University Biomedical Applications 
Team and Rositano recognized the potential value 
of the NASA electrode to the medical field. 
Rositano was invited to present a paper on the 
NASA electrode at a conference at Stanford 
University. Approximately 200 representatives 
of NASA, industry, and the medical community had 
been invited. As a result of that conference and 
subsequent communications between a manufacturer 
and NASA, the flexible long-term monitoring elec­ 
trodes were made commercially available. The 
manufacturer modified the material slightly to 
minimize off-set potentials; otherwise, the 
commercial electrodes were the same as the NASA 
electrode.
Case 2: Biological Tissue Freezing System 
(Design Transfer)
The need to freeze, store, and subsequently thaw 
healthy tissue without damage is an important 
requirement. For example, transfusions of white 
cells are frequently used in the treatment of 
leukemia and a method of storing white cells is 
needed. Commercially available tissue freezing 
units damage a large fraction of the cells in 
tissue.
Cell damage in the freezing process is thought to 
result from a lack of precise control over the 
rate of cooling. At the tissue freezing tempera­ 
ture, the latent heat of the tissue is released 
and the rate of cooling is drastically lowered.
The RTI Biomedical Applications Team discussed 
this medical requirement in detail with an 
engineer and medical researcher at the National 
Cancer Institute (NCI) in 1970. A Problem State­ 
ment concisely describing that requirement was 
written and circulated to NASA Field Centers. 
Engineers at NASA's Jet Propulsion Laboratory 
(JPL) recommended an innovative technological 
solution.
The concept proposed by JPL engineers is il­ 
lustrated in Figure 3. This concept involves 
placing the biological tissue in close proximity 
to a sufficient quantity of liquid nitrogen to 
freeze the material very rapidly. Electrical 
resistance heating elements are placed between the 
container of biological tissue and the liquid 
nitrogen containers. By precisely monitoring the 
temperature at the surface of the tissue container,
the amount of electrically generated thermal 
energy injected at the tissue-liquid nitrogen in­ 
terface can be adjusted rapidly to give precise 
control of the tissue temperature. Two inno­ 
vations are involved in this concept: (1) the 
approach to control of cooling rate; and, 
(2) precise temperature monitoring technology 
developed by JPL for use in space.
Initial evaluations of the concept by NASA en­ 
gineers, the Biomedical Applications Team, and 
NCI were positive. Because it is located close 
to NCI, NASA's Goddard Space Flight Center was 
selected to design and fabricate a prototype 
tissue freezing unit for evaluation at NCI. 
Experiments in freezing and thawing human and 
animal tissue at NCI indicated that the NASA 
freezing unit could control freezing rates and 
that stem cells and white cells could be frozen 
and thawed with little cell damage.
Following validation of the freezing concept, JPL 
engineers discussed the freezing unit, its suc­ 
cess, and its potential applications with a number 
of manufacturing firms. At present, JPL, with 
significant funding from industry, is conducting 
R & D to better understand the freezing process 
and to generate data for designing freezing units 
for specific applications.
Case 3: Clinical Information System 
(Capacity Transfer)
For a number of years, Duke University Medical 
Center staff have been developing a clinical in­ 
formation system with the objective of improved
medical care for patients with ischemic heart
1 S —1 7 disease. J *-' This medical information system
contains the medical histories of over 4,000 Duke 
University Medical Center ischemic heart disease 
patients. Information on disease state, medical 
treatment, and patient response as well as in­ 
formation on the patient's lifestyle are stored. 
A physician at Duke University Medical Center can 
obtain medical histories on a specific patient 
profile that matches a patient presently being 
treated. For example, the physician can obtain 
medical treatments and patient responses for 
patients in a particular age group, with certain 
smoking habits, and with particular disease 
symptoms. The system is proving to be a signifi­ 
cant asset to the medical center staff.
Early in the development of this information sys­ 
tem, C. F. Starmer, Duke University Medical 
Center, was attempting to develop a computer-based 
system to identify and track the movement of nodes 
in the coronary arterial trees recorded in biplane 
cineangiograms. Discussions between Starmer and 
the RTI Biomedical Applications Team identified 
the image processing work at JPL as technology 
relevant to Starmer's investigations. The RTI 
team was able to assist Starmer in obtaining a 
summer fellowship at the Jet Propulsion Laboratory 
in 1970. As a result of his summer fellowship at 
JPL and his continued communications with NASA 
engineers, Starmer became knowledgeable of NASA 
image processing technology which over a period
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of years was introduced into the medical center 
clinical information system. Specifically, NASA 
technology contributed to: (1) an easy-to-use 
mechanism for inputting and storing graphic data; 
and (2) a data storage system that facilitates 
the use of accumulated patient data to develop 
meaningful prognoses.
MEDICAL TRANSFER CASE ANALYSIS
Examples of material, design, and capacity tech­ 
nology transfers in medicine have been presented. 
Understanding of the technology transfer process 
and of the participants' roles in that process 
is enhanced by considering the relative involve­ 
ment of the participants in these three examples 
as summarized in Table 1.
TABLE 1 
MEDICAL TECHNOLOGY TRANSFER CASE SUMMARY
Case Number
Level of Transfer
Transfer Agent Involvement
Donor Involvement
Recipient Involvement
1
1
M
H
L
2
2
H
H
H
3
3
L
L
H
Notes: H—High level of involvement
M—Moderate level of involvement 
L—Low level of involvement
Transfers at the material level within the con­ 
text of applying aerospace technology in the 
medical field are infrequent. Even in the case 
presented, body surface electrodes, the tech­ 
nology was modified before becoming a commercial 
product. The involvement of the recipient, the 
medical community, was to confirm the medical 
utility of the NASA electrode. On the other 
hand, the involvement of the donor appears to 
have been relatively high in that NASA was in­ 
volved in developing the electrode and in trans­ 
ferring required data and information to the 
manufacturer. The involvement of the transfer 
agent was to identify, in collaboration with the 
donor organization, the potential for technology 
transfer and to facilitate communications between 
NASA, the medical community, and industry. This 
is estimated to have been a moderate level of 
involvement.
The second example, the biological tissue 
freezing system, is clearly a design transfer. 
A significant development, design, and fabri­ 
cation effort was required in building the pro­ 
totype units. This effort was performed by NASA 
and constitutes a high level of donor involve­ 
ment. The recipient, NCI, identified the 
requirement for the system, specified functional 
characteristics of the freezing unit, acted as 
consultant to Goddard Space Flight Center during 
development and design of prototypes, and 
evaluated the system through extensive experi­ 
mental work. This certainly constitutes a high 
level of recipient involvement. The transfer
agent, the RTI Biomedical Applications Team, was 
involved throughout the transfer process in com­ 
municating the medical requirements to NASA, in 
communicating potential solutions to NCI, in 
coordinating the collaborative effort between 
NASA and NCI, in avoiding potential barriers in 
the transfer process, and in documenting the 
process and the transfer. During the prototype 
evaluation at NCI, the medical researcher who 
had worked with the team in specifying the 
medical requirement left NCI and the experimental 
evaluation was temporarily terminated. Because 
of the continued involvement of the RTI team and 
the commitment to the project by other individuals 
at NCI, the evaluation was continued after a 
relatively short delay. It is judged that the 
involvement of the donor, recipient, and transfer 
agent were high throughout the transfer process, 
and further, that this level of involvement was 
critical to the success of the transfer process.
Case No. 3, clinical information system,is an 
excellent example of a capacity transfer. The 
involvement of the transfer agent, the RTI team, 
was low. That involvement was assistance to 
Starmer in obtaining a summer fellowship at JPL. 
The involvement of the donor, NASA, was likewise 
relatively low. On the other hand, the recipient 
was intimately and extensively involved in NASA's 
image processing technology and in applying that 
technology in the clinical information system 
over a period of years.
The nature of material transfers as illustrated 
by the body surface electrode case can be 
characterized as a response by the donor to a 
transfer opportunity. Identifying such op­ 
portunities is highly dependent upon the presence 
of individuals aware of both medical requirements 
and technologies available in donor organizations. 
Marketing is the major activity in material 
transfers.
Design and capacity transfers are a long-term 
process involving years of effort. Significant 
commitments of resources by the donor, recipient, 
or industry are required.
A high level of involvement on the parts of donor, 
recipient, and transfer agent are critical to the 
success of design technology transfers. In the 
case of capacity transfers, the recipient bears 
the burden of the effort.
In each of the three cases presented, the first 
step in the transfer process was the identi­ 
fication or confirmation of a medical requirement. 
Thus, these transfers can be characterized by 
"need-pull" as opposed to "technology-push."
In both design and capacity transfers,a transfer 
agent is essential either within the donor 
organization or having a strong association with 
the donor organization. The NASA-sponsored 
Biomedical Applications Teams appear to be ful­ 
filling this role with increasing effectiveness.
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CONCLUSIONS
NASA's Biomedical Applications Team program is 
effectively transferring aerospace technology to 
applications in medicine. These transfers are 
occuring at the material, design, and capacity 
levels with most of the activity occuring at the 
latter two levels.
NASA's Technology Utilization Program objectives 
and the present state of health care delivery 
have guided the Biomedical Applications Teams in 
establishing program emphasis. That emphasis is 
upon transferring technology via the introduction 
of commercially available, medical products that 
incorporate NASA technology. Further, emphasis 
is upon applying technology to improve medical 
diagnosis and treatment or to contain medical 
costs.
Successful technology transfer in medicine re­ 
quires a continuing involvement of the donor, 
recipient, and transfer agent in the transfer 
process. Additionally, industry must be involved 
early in the transfer process when a commercial 
product is involved.
Successful technology transfer is, in general, a 
long-term process. The commitment of significant 
resources is required by the donor, recipient, 
or industry on a long-term basis.
Continued study of horizontal technology transfer 
in medicine and within the context of com­ 
mercialization will result in greater program 
productivity. Increased understanding of 
government-industry linkages formed in technology 
transfer is essential.
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ILLUSTRATIONS
Figure 1. Conceptual Framework.
Figure 2. Biomedical Applications Team 
Methodology.
Figure 3. NASA Tissue Freezing Unit.
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